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Multiple endocrine neoplasia type I (MEN1) is a familial cancer syndrome characterized primarily by tumors of multiple
endocrine glands. The gene for MEN1 encodes a ubiquitously expressed tumor suppressor protein called menin. Menin
was recently shown to interact with several components of a trithorax family histone methyltransferase complex
including ASH2, Rbbp5, WDR5, and the leukemia proto-oncoprotein MLL. To elucidate menin’s role as a tumor
suppressor and gain insights into the endocrine-specific tumor phenotype in MEN1, we mapped the genomic binding
sites of menin, MLL1, and Rbbp5, to approximately 20,000 promoters in HeLa S3, HepG2, and pancreatic islet cells
using the strategy of chromatin-immunoprecipitation coupled with microarray analysis. We found that menin, MLL1,
and Rbbp5 localize to the promoters of thousands of human genes but do not always bind together. These data
suggest that menin functions as a general regulator of transcription. We also found that factor occupancy generally
correlates with high gene expression but that the loss of menin does not result in significant changes in most transcript
levels. One exception is the developmentally programmed transcription factor, HLXB9, which is overexpressed in islets
in the absence of menin. Our findings expand the realm of menin-targeted genes several hundred-fold beyond that
previously described and provide potential insights to the endocrine tumor bias observed in MEN1 patients.
Citation: Scacheri PC, Davis S, Odom DT, Crawford GE, Perkins S, et al. (2006) Genome-wide analysis of menin binding provides insights into MEN1 tumorigenesis. PLoS Genet
2(4): e51. DOI: 10.1371/journal.pgen.0020051
Introduction
The hallmark of multiple endocrine neoplasia type I
(MEN1), is the development of tumors in the parathyroid,
anterior pituitary, and enteropancreatic endocrine cells.
Other associations occasionally found in MEN1 patients
include foregut carcinoids, facial angioﬁbromas, lipomas,
collagenomas, meningiomas, and smooth muscle tumors.
MEN1 patients typically inherit loss of function mutations in
the MEN1 gene, and tumors arise following loss of the
remaining wild-type allele. Thus, the MEN1 gene follows the
classic ‘‘two-hit’’ tumor suppressor model ﬁrst proposed by
Knudson for retinoblastoma [1]. Somatic mutations in the
MEN1 gene are also frequently found in sporadic parathyroid
adenomas, insulinomas, gastrinomas, and lung carcinoids [2–
6], indicating that loss of the MEN1 gene is a major
contributor to the development and maintenance of many
nonhereditary endocrine tumors. There is currently no
prevention of or cure for MEN1 cancers, and cancer treat-
ment options are generally limited to surgical interventions.
The protein product of MEN1, menin, is a ubiquitously
expressed 67-kDa protein found predominantly in the
nucleus [7]. Studies in Men1 knockout mice support menin’s
role as a tumor suppressor [8,9]. Mice that are homozygous
null for Men1 show developmental defects and die at
embryonic day 11.5 to 13.5. Heterozygous Men1 mice
eventually develop multiple endocrine tumors that arise
following somatic loss of the wild-type Men1 allele, and the
spectrum of tumors observed in Men1
þ/  mice is remarkably
similar to that in human MEN1 kindreds. We and others have
also successfully developed conditional knockouts of the
Men1 gene, using the Cre-lox system [10–12]. When homo-
zygous Men1 ‘‘ﬂoxed’’ mice are bred to animals expressing
Cre recombinase in the beta cells of the pancreatic islets, the
resultant progeny develop multiple pancreatic insulinomas.
These insulinomas arise long after homozygous inactivation
of the Men1 gene, suggesting that additional somatic events
are required for frank tumor formation. Men1
 /  insulinomas
are capable of developing in the absence of chromosomal or
microsatellite instability, suggesting that the additional
somatic events required for tumor formation are subtle,
occurring at either the nucleotide or epigenetic level [13].
Although inherited mutations in the MEN1 gene predispose
individuals to several types of tumors, there is a particularly
striking predisposition to tumors in endocrine tissues. The
development of tumors in this endocrine-speciﬁc pattern is
quite puzzling as menin appears to be expressed in all tissues.
In a previous study, we set out to gain insights to this issue of
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transgenic mice expressing Cre recombinase from the albumin
promoter, which is predominantly expressed in liver hepato-
cytes [14]. This strategy allowed us to assess the loss of menin
in liver, a tissue not normally predisposed to developing
tumors in humans or mice with heterozygous MEN1 loss of
function mutations. Progeny that were homozygous for a
ﬂoxed Men1 allele and expressing Cre showed a nearly
complete loss of Men1 mRNA and corresponding protein
levels in the liver, yet the overwhelming majority of menin-
null livers were histologically normal and remained tumor
free. These ﬁndings suggest that in liver, menin’s tumor
suppressor function or functions are dispensable.
Menin has been reported to interact with a multitude of
proteins including JunD, SMAD family members, Pem, NFjB,
FANCD2, RPA2, NMMHC II-A, GFAP, vimentin, and Hsp70
[15]. The diverse functions of the menin partners suggest
roles for menin in transcriptional regulation, DNA process-
ing and repair, cytoskeletal organization, and protein
degradation, although to date none of the interacting
partners have been directly proved important in MEN1
pathophysiology. No convincing evidence of direct binding of
menin to DNA has been shown, but menin has been shown to
associate with a multimember protein complex whose
composition is highly similar to that of the SET1 histone
methyltransferase complex of yeast and humans [16,17].
Members of this complex include HCF-2 (host cell factor 2),
Rbbp5 (retinoblastoma binding protein 5), WDR5 (WD repeat
domain 5), and trithorax proteins MLL1/MLL2 (mixed-
lineage leukemia) and ASH2 (absent, small, or homeotic).
The menin-HMT–associated complexes promote methylation
of histone H3 tails at lysine 4 (H3 K4), an epigenetic mark that
is generally associated with active gene transcription. At the
time of this study, ﬁve target genes positively regulated by
menin and MLL have been reported in various tissues [16–19].
These targets include the clustered homeobox genes, HOXA9,
c6, and c8, and two cyclin-dependent kinase (CDK) inhibitors
involved in cell cycle regulation, p27
Kip1 and p18
Ink4c.
It has been hypothesized that menin mediates its tumor
suppressor action by regulating histone methylation in
promoters of HOX genes and/or p18, p27, and possibly other
CDK inhibitors [18,19]. Consistent with this hypothesis, H3 K4
methylation and expression of p18 and p27 were shown to be
dependent on menin in pancreatic islets [18]. An additional
clue for a role for p18 and p27 in MEN1 pathophysiology
comes from studies in knockout mice [20]. The simultaneous
loss of p18 and p27 in mice leads to a tumor spectrum that is
similar to that in human MEN1 and MEN2 patients, including
tumors in the pituitary, parathyroid, thyroid, endocrine
pancreas, stomach, and duodenum. These ﬁndings raise
critical questions regarding the function of menin and the
basis of endocrine-tumor formation in MEN1. (1) Does menin
mediate its tumor suppressor action by governing the
expression of HOX and cell cycle genes alone or through
additional key targets that have not yet been identiﬁed? (2)
Does menin only target genes whose transcription is trithorax
dependent, or can menin also target genes independently of
MLL and its associated HMT complex members? (3) Could
the speciﬁc bias for endocrine tumor formation in MEN1
result from differences in distinct genes that are targeted by
menin in the endocrine tissues?
To gain a more complete understanding of the action of
menin tumor suppression, we identiﬁed the genomic occu-
pancy of menin and two associated HMT complex members,
MLL1 and Rbbp5, using chromatin immunoprecipitation
coupled with DNA microarray analyses (ChIP-chip) [21].
Given the evidence that the menin-HMT complex methylates
histone H3 at lysine 4 [16,18], we also mapped the positions of
H3 K4 (trimethylation) by ChIP-chip. Our data in HeLa S3,
HepG2, and human pancreatic islet cells indicate that menin
occupies the promoter regions of thousands of human genes,
suggesting that menin acts as a global regulator of tran-
scription. Menin occupancy frequently coincides with MLL1,
Rbbp5, and H3 K4, but menin can also target promoters
independently of the HMT complex. Factor occupancy
generally correlates with high gene expression, and loss of
menin in pancreatic islets, by and large, does not affect
transcript levels. Last, we present a model for tumor
suppression by MEN1 and offer insights into the endocrine
tumor bias observed in MEN1 patients.
Results
Pattern of Menin Binding at HOX Clusters and Elsewhere
We set out to investigate the genomic occupancy of menin
using ChIP-chip. Recent evidence suggesting that menin
associates with an SET1-like HMT complex to regulate HOX
gene expression [16,17] prompted us to design a microarray
containing oligonucleotides tiled at high density across the
HOX A, B, C, and D loci. To determine if menin preferentially
binds to genes that contain homeobox domains, our arrays
also included oligonucleotides corresponding to more than
100 homeodomain-containing genes located outside of the
four HOX clusters. We also tiled probes corresponding to
approximately 20 megabases (Mb) of random sequence on
Chromosome 7, to assess menin occupancy in regions located
at large distances from genes. As a pilot effort, we hybridized
these HOX-centered microarrays with menin-chromatin
immunoprecipitated DNA from HeLa S3 cells. A computer
program incorporating a sliding window and threshold
approach, ACME (Algorithm for Capturing Microarray
Enrichment), was used to identify genomic sites enriched
for menin-binding (Figure 1).
Hybridizations to these HOX arrays with menin-chromatin
immunoprecipitated DNA from HeLa S3 cells revealed
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Synopsis
In multiple endocrine neoplasia type I, absence of the nuclear factor
menin gives rise to endocrine tumors by a mechanism that is poorly
understood. Using state-of-the-art genome-wide chromatin-immu-
noprecipitation coupled with microarray analysis technology, this
paper significantly enlarges our understanding of the role of menin
by greatly extending the number of gene targets where menin
binds. The authors show that while menin frequently colocalizes
with a protein complex that modifies chromatin structure, menin
c a na l s ob i n dt om a n yo t h e rp r o m o t e r sb ya na l t e r n a t i v e
mechanism. They also present data that potentially implicate one
of the menin target genes, HLXB9, in the endocrine specificity of
tumorigenesis in multiple endocrine neoplasia, type 1. Further
experiments to confirm the role of HLXB9 in tumorigenesis are
necessary and may help explain how the loss of a ubiquitously
expressed tumor suppressor gene can give rise to tumors in specific
tissues.striking differences between menin occupancy at the clus-
tered HOX genes as compared to elsewhere. For genes located
outside the four HOX clusters, menin was frequently localized
to 59 promoter regions, at or very near transcriptional start
sites (Figure 2A and 2B). Little to no signal was detected in
intragenic regions, or at 39 untranslated regions. Menin
occupancy at the HOX clusters was more extensive, with
broad footprints that spanned intergenic and intragenic
portions of HOX genes (Figure 2C). Speciﬁcally, within the
HOX A cluster, menin sites clustered at HOXA6, A10, A11, and
Figure 1. Strategy Used to Analyze Data from Tiled Microarrays
(A and B) Scatterplots of single-array intensities of oligonucleotides obtained from chromatin immunoprecipitation with menin antibodies (B) and a
control with no antibody (A). Successful experiments are identified as those that show enrichment of multiple probes in the Cy5 channel (chromatin
immoprecipitated DNA) over the Cy3 channel (total genomic DNA).
(C) Histogram of mean intensity ratios (log2 scale) from menin chromatin immunoprecipitations from three biological replicates. The distinct tail at the
right-hand end corresponds to DNA fragments enriched by menin-ChIP. Genomic sites enriched for factor binding are identified using a computer
program called ACME. ACME first sorts probes by their genomic location, and then slides a window of user-defined size along tiled regions. ACME then
tests whether each window contains a higher than expected number of oligonucletide probes above a user-defined threshold, and then assigns a p-
value to each probe on the array. For all arrays used in this study, the window was set to 1,000 bp and the threshold at 90% (indicated by the red bar).
(D) Plots showing data before and after processing by ACME. Points in black represent the mean intensity ratio of oligonucleotide probes (right y axis).
Points in red indicate corresponding significance values for each data point reported by ACME (left y axis). True-positive signals are represented by
multiple probes that cluster within a given window. Single probes that yield high intensity ratios most likely represent noise and are automatically
filtered out by the windowing/threshold analysis.
DOI: 10.1371/journal.pgen.0020051.g001
Figure 2. General Pattern of Menin Occupancy in HeLa S3 Cells
(A) Tiled oligonucleotides corresponding to a random 3 MB on Chromosome 7. Four positive signals indicative of menin occupancy are denoted by the
arrows and are easily distinguishable from background noise.
(B) Expanded view of one positive signal from (A) reveals multiple oligos with significant p-values clustered solely at the transcriptional start site of
SNX13 (Sorting Nexin 13).
(C) Pattern of menin occupancy at each of four homeobox clusters.
DOI: 10.1371/journal.pgen.0020051.g002
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Genomic Occupancy of MeninA13. Extensive binding to the HOX C cluster was also
detected, with broad signals that extended across HOXC11,
C10, C9, and portions of C4 and C6. Menin sites were also
detected near HOXB6 and HOXB7, but the pattern of binding
was less extensive than that detected at the HOX A and C loci.
No signiﬁcant menin binding was detected at the HOX D
locus. Menin sites were also detected at several other
homeobox genes located outside the four HOX clusters, but
similar to other non-HOX loci, binding was localized to 59
promoter regions (unpublished data). Our ﬁnding that menin
binds to HOXA9, C6, and C8 is consistent with prior studies in
which these three HOX genes were identiﬁed by standard
ChIP-PCR [16,17] and supports the reliability of the ChIP-
chip methodology used here for detecting genomic binding
events by menin.
Genome-Wide Distribution of Menin in Multiple Cell Types
The results of the pilot study above indicate that, except for
the HOX clusters, menin occupancy is highly speciﬁc for 59
regions of genes. Based on these ﬁndings, we rationalized that
menin sites could be identiﬁed on a near genome-wide scale
by interrogating only those regions of DNA that correspond
to the 59 portions of genes. We therefore designed a second
DNA microarray containing tiling oligonucleotides across the
59 regions of approximately 20,000 human genes. Given the
binding pattern of menin at the HOX clusters, this array also
contained tiled oligos across all four clustered HOX loci, as
well as the complete sequence of 381 genes ( 5,000 bp relative
to the transcription start site to þ5,000 bp relative to the
transcription stop site) that showed evidence of menin
occupancy on previous arrays (PCS, unpublished data). These
promoter arrays were hybridized with menin-chromatin
immunoprecipitated DNA from human islets, HeLa S3 and
HepG2 cells. To assess if the bias for endocrine-tumor
formation in MEN1 might be related to differences in distinct
target genes in endocrine cells, we compared sites occupied
in HeLa S3 and HepG2 cells to those identiﬁed in human
pancreatic islet cells. As expected, hybridizations with menin-
chromatin immunoprecipitated DNA from HeLa S3 cells
revealed broad signals at the HOX clusters and promoter-
speciﬁc signals at most other loci (Figure 3A and 3B). In
HepG2 and pancreatic islet cells, the vast majority of menin
sites were also detected in promoter regions, at or near
transcriptional start sites. Notable differences in the pattern
of menin binding were detected at the HOX clusters. Whereas
multiple menin sites were detected at the HOX A and C
clusters in HeLa cells, relatively little signal was detected at
these clusters in HepG2 cells and pancreatic islets (Figure 3A
and unpublished data). By using a stringent selection
criterion of p , 0.0001, we found that menin occupies
1,706 sites in HeLa S3 cells, 2,239 sites in HepG2 cells, and
1,541 sites in pancreatic islet cells. Sites that were concordant
and discordant between each cell type are depicted in a Venn
diagram (Figure 3C). The ﬁnding that menin binds to a broad
range of human promoters in all three cell types suggests that
menin has a global role in transcription in both endocrine
and non–endocrine-derived cells.
Overlap of Genomic Occupancy of Menin, MLL, Rbbp5,
and the H3 K4 Trimethyl Mark
Based on published evidence that menin associates with a
HMT complex containing MLL, Ash2L, WDR5, and Rbbp5,
we set out to determine if the genomic occupancy of menin
coincides with two other members of this complex, MLL1 and
Rbbp5. Given the ability of the SET1/MLL complex to
catalyze the trimethlyation of histone H3 at lysine 4, we also
mapped the genomic distribution of the H3 K4 trimethyl
mark. Results for the HOX A cluster are shown in Figure 3A,
where the binding patterns for menin, MLL1, Rbbp5, and H3
K4 are seen to be similar, although menin shows a more
contiguous binding pattern across HOXA9, A10, A11, and A13.
For non-HOX promoters, different binding combinations
were seen for different promoters; for illustration, Figure 3B
displays a promoter where all factors bind near the tran-
scriptional start site, but that was not always the case.
It is not uncommon for ChIP-chip data to reveal dramatic
differences in the intensity of hybridization signals at multi-
ple loci [22]. While some loci appear highly enriched, others
appear modestly enriched, and other loci entirely lack signal.
Differences in signal intensities could reﬂect true differences
in occupancy of the factor or could represent slight differ-
ences in ampliﬁcation or hybridization of chromatin immu-
noprecipitated DNA. Because of the broad dynamic range in
signal, assessing the overlap between different factors at
multiple loci at a given signiﬁcance threshold locus can be
challenging (Figure 4A). To depict the overlap more
accurately between sites occupied by each factor, we selected
promoters that were occupied by menin and MLL1 at high
conﬁdence (p , 0.0001), and then plotted the corresponding
p-values for each associated factor as a heatmap. Heatmaps
from all three cell types indicate that a large proportion of
promoters are bound by all factors (Figure 4B and 4C). The
data also reveal distinct sets of promoters occupied by menin
and not MLL1 or Rbbp5, and vice versa. Setting stringent
cutoffs for bound (p , 0.0001) and unbound (p . 0.1), the
percentage of menin sites that were also bound by MLL1 and
Rbbp5 were as follows: 49.3% in HeLa S3 cells; 56.7% in
HepG2 cells, and 46.1% in pancreatic islets. The percentage
of menin sites that did not coincide with both MLL1 and
Rbbp5 was lower: 21.7% in HeLa cells, 9.5% in HepG2 cells,
and 2.4% in pancreatic islets. These results suggest that
menin targets promoters in cooperation with HMT complex
members MLL1 and Rbbp5, but that menin can also occupy
promoters in cooperation with other unidentiﬁed factors
that may not be part of the HMT complex.
Validation of Factor Binding by Real-Time PCR
We used a standard approach that combines conventional
ChIP and real-time PCR to assess the reliability of the ChIP-
Figure 3. Occupancy of Menin, MLL, Rbbp5 Frequently Overlaps with Trimethylation of Lys4 at Histone H3
(A) Compared to occupancy at the HOX A cluster in HeLa cells, factor occupancy in HepG2 cells and pancreatic islets is nearly absent.
(B) Overlap of factors at one representative locus, ASB3 (Ankyrin repeat- and Socs Box-containing protein 3).
(C) Venn diagram showing the overlap of menin-bound promoters in HeLa S3, HepG2, and pancreatic islets. Promoters included in the tally had a
confidence threshold of p , 0.0001.
DOI: 10.1371/journal.pgen.0020051.g003
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Genomic Occupancy of Meninchip method and our approach for analysis of the raw
microarray data (Figures 4D and 5). We arbitrarily selected 67
promoter regions that were identiﬁed by our windowing and
threshold analyses to be enriched for menin binding at p ,
0.0001. These sites were compared to 15 random promoter
regions (0.001 , p , 1) and seven random regions of the
genome located outside of promoter regions. On average,
promoters that had a p-value of ,0.0001 were enriched 7.25-
fold over random regions (Figure 5A). Furthermore, of the 67
sites that were shown to be enriched by ChIP-chip (p ,
0.0001), 64 (95.5%) were conﬁrmed by real-time PCR to have
enrichment ratios that were greater than those detected for
the randomly selected ampliﬁed regions. These data indicate
that sites we determined to be enriched at p , 0.0001 by
ChIP-chip reliably detect enriched sites of menin binding.
Many factor-bound sites probably also exist within the p ¼
0.01 to 0.001 conﬁdence interval, but negative control studies
suggest that false-positive rates increase as p-values rise above
0.0001 (Figure 5C). Relative enrichment using antibodies to
H3 K4 was also tested (Figure 5B). Consistent with the tight
physical association between DNA and histones, enrichment
of H3 K4–bound sites was greater than that for menin sites.
Comparison of ChIP-Chip and Gene Expression
The ChIP-chip data in all three cell types indicate that
menin occupancy frequently coincides with trimethylation of
histone H3 at lysine 4, a mark that is generally associated
with a transcriptionally active state of chromatin. These
results prompted us to assess whether factor occupancy
correlates with high levels of gene expression. A systematic
comparison between ChIP-chip and expression data in all
three cell types revealed that genes whose promoters are
bound by menin correlate with higher mRNA expression
levels (Figure 6A and unpublished data). This was true for
gene subsets both where menin bound concordantly with
MLL and Rbbp5 and where menin bound without these
factors. These data suggest that menin, in both the presence
and absence of the HMT complex, is generally associated
with transcriptionally active promoters.
Figure 4. Menin Sites Can Be Bound in the Presence or Absence of HMT Complex Members
(A) Comparison of promoters bound by menin and Rbbp5 showing the broad range in signal intensity for each factor. The log10 p-value for each site
is plotted on the x and y axes. Vertical and horizontal lines represent confidence thresholds at p , 0.0001. Points in the lower left quadrant represent
promoters that are bound by neither menin nor Rbbp5. Points in the upper right quadrant represent promoters occupied by both menin and Rbbp5.
Plots comparing menin to MLL and H3 K4 appeared similar (unpublished data).
(B and C) Heat maps illustrating the overlap of factor-occupied promoters. Promoters bound by either menin (B) or MLL (C) at the p , 0.0001
confidence threshold in HeLa S3 cells were plotted with corresponding p-values for each indicated factor. The heat maps reveal subsets of genes that
are bound by all factors (blue brackets), in addition to subsets that are bound by menin or MLL but not the other factors (green brackets).
(D) Real-time PCR validation of randomly selected promoters determined by ChIP-chip to be bound by menin and not Rbbp5 (left), and vice versa
(right). Each pair of bars corresponds to a unique promoter region.
DOI: 10.1371/journal.pgen.0020051.g004
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Genomic Occupancy of MeninComparison of ChIP-Chip and Expression Data from Mice
That Are Conditionally Null for Men1
The ChIP-chip and expression data indicate that menin
targets a broad range of promoters that are generally
transcriptionally active. Given these ﬁndings, one might
predict that menin may function to maintain steady-state
gene expression and that loss of menin might lead to reduced
expression of genes normally targeted by menin and the HMT
complex. To test whether menin-targeted genes show alter-
ations in expression in cells that lack menin, we determined in
vivo expression changes incurred upon menin loss in a mouse
model of MEN1. Speciﬁcally, we compared human ChIP-chip
data to expression data from islets isolated from wild-type
mice or from mice that were conditionally null for Men1 in the
beta cells (genotype: RIP-cre; Men1
loxP/loxP). Islets from these
mice develop tumors long after (30 to 50 wk) homozygous
Figure 5. Enrichment of Selected Genomic Regions
Real-time PCR testing of genomic regions from menin (A) and H3 K4 (B) chromatin immunoprecipitations. Median values are indicated by the red bars.
Enrichment values for menin are less than 1 because Ct values for the menin ChIP-PCR were higher than that for total genomic DNA (see Materials and
Methods).
(C) Number of promoters bound by each factor in HeLa S3 cells at various p-values. Compared to a negative control experiment in which no antibodies
were used in the ChIP (protein G), significant enrichment of promoters was detected for each factor analyzed.
DOI: 10.1371/journal.pgen.0020051.g005
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Genomic Occupancy of Menininactivation of the Men1 alleles and thus provide the
opportunity to detect expression changes more closely related
to menin loss than at later stages of neoplastic trans-
formation, when secondary activating or inactivating muta-
tions have accumulated. Microarray analyses were performed
using RNA from highly puriﬁed pancreatic islets isolated from
15- and 25-wk mice that were conditionally null for Men1.
Controls included islets from age- and sex-matched wild-type
and RIP-cre transgenic animals. At 15 wk, Men1
 / islets appear
relatively normal in size and morphology. By 25 wk, the
majority of Men1
 /  pancreatic islets appear hyperplastic and
occasionally contain small adenomatous lesions [12].
Similar to the results of previous comparisons between
ChIP-chip and gene expression data, genes whose promoters
were bound by menin (p , 0.0001) correlated with high
expression in wild-type mouse islets (Figure 6B). Contrary to
what one might predict given the broad range of promoters
targeted by menin, we did not detect signiﬁcant differences
in the expression of menin-targeted genes in 15- and 25-wk
menin-null islets compared to wild-type (Figure 6B). Since
overall expression levels remained generally unchanged in
the null state, we turned our attention to the exceptions.
One hundred eighty-four individual genes whose promoters
were bound by menin in wild-type human islets showed
alterations in expression in Men1 null mouse islets at the 15-
wk time point (Figure S1). Of these 184 genes, 110 were
upregulated in the absence of menin and 74 were down-
regulated. Consistent with the prior evidence suggesting that
menin positively regulates p18 in islets [18], p18 (CDKN2C)
was found to be signiﬁcantly reduced in expression in
Men1
 /  islets.
Analysis of Hlxb9
Given the speciﬁc bias for endocrine tumor formation in
MEN1, we focused on genes that were bound by menin in
islets and not in HeLa S3 or HepG2 cells, and whose
expression was altered in menin-null islets. Twenty-four such
genes were found; 12 of these were upregulated in menin-null
islets compared to wild-type islets and 12 were downregu-
lated. Of these 24 genes, only seven were signiﬁcantly
different at both the 15- and 25-wk time points. One of these
candidates was the transcription factor Hlxb9. HLXB9
encodes HB9, a homeodomain protein predominantly ex-
pressed in adult pancreas and developing motor neurons
[23,24]. Of particular interest, HLXB9 is key to normal
pancreas development and function, and mice that are
homozygous null for Hlxb9 fail to develop the dorsal lobe of
the pancreas [25,26]. The remnant Hlxb9
 / - pancreas has
small islet cells, with reduced numbers of insulin-producing
beta cells. Early overexpression of Hlxb9 in pancreatic
epithelium results in a complete disruption of pancreatic
development [27]. In humans, dominantly inherited loss of
function mutations in HLXB9 causes Currarino syndrome, a
developmental disorder characterized by partial sacral
agenesis, a presacral mass, and anorectal and urogenital
malformations [28–30]. Activation of HLXB9 expression may
be induced by chromosomal rearrangements in acute
lymphoblastic leukemia [31,32].
To test the possibility that menin regulates beta cell–
speciﬁc expression of Hlxb9 and to validate the microarray
results described above, we measured gene expression by RT-
PCR in Men1
 /  pancreatic islets and islet tumors isolated
from a cohort of conditionally null Men1 mice (Figure 7).
Compared to islets isolated from wild-type mice, expression
of Hlxb9 was signiﬁcantly increased in 15- and 25-wk Men1
 / 
islets. Consistent with these ﬁndings, immunohistochemical
analyses in a conventional Men1 knockout animal revealed
increased Hb9 expression in atypical hyperplastic islets and
tumor tissue. Collectively, these ﬁndings suggest activation of
Hlxb9 in response to menin loss might contribute to islet beta
cell tumorigenesis.
Menin Occupancy at p18 and p27 Loci
Recent reports suggesting that menin can positively
regulate p18 and p27 [18] prompted us to investigate ChIP-
chip and expression data at these two loci. We detected
Figure 6. Factor Occupancy Correlates with High Gene Expression but
Absence of Menin Does Not Generally Affect Gene Expression Levels
(A) Overall expression of genes for which we had both expression and
binding data in HeLa S3 cells was plotted (lane 1, ‘‘All expression’’) and
compared to the expression of genes whose promoter regions were
bound (p , 0.0001) by each of the factors indicated at the top. Asterisks
denote significance (p , 0.0001) as determined by two-tailed t-test
analyses between each set of factor-bound genes compared to all genes.
Box plots comparing ChIP-chip and expression data from HepG2 and
pancreatic islets revealed similar correlations between expression and
factor occupancy (unpublished data).
(B) Overall expression of genes in islets isolated from wild-type control
mice (lane 1, ‘‘All Expression’’) compared to those normally bound by
menin in wild-type islets (lane 2) and those normally bound by menin in
islets from 15-wk (lane 3) and 25-wk (lane 4) mice that are conditionally
null for Men1 (genotype: RIP-cre; Men1
 / ).
DOI: 10.1371/journal.pgen.0020051.g006
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Genomic Occupancy of Meninintense ChIP hybridization signals for menin, MLL, and H3
K4 trimethylation at the promoters of both p18 and p27 in
HeLa S3, HepG2, and pancreatic islet cells. Menin, MLL, and
H3 K4 occupancy at p18 and p27 loci also coincided with
Rbbp5 binding in HeLa and HepG2 cells but not in
pancreatic islets. Consistent with previous ﬁndings [18], we
detected reduced expression of p18 in Men1
 /  islets by
microarray analyses (Figure S1), and this was validated by
real-time RT-PCR (unpublished data). Alterations in p27
expression levels were not detected in null islets.
Given that menin was found by ChIP-chip to occupy p18
and p27 in all three cell types, we next set out to determine if
the absence of menin affects p18 and p27 expression levels in
a nonendocrine tissue. In an effort to gain insights into tissue
speciﬁcity in MEN1, we previously used the Cre-lox system to
generate mice that are homozygous null for Men1 in liver [14].
Mice with Men1
 /  livers showed a nearly complete loss of
Men1 mRNA corresponding protein levels, yet the menin-null
livers remain tumor free. To assess if menin maintains p18
and p27 expression in liver, we measured p18 and p27 gene
expression by RT-PCR in liver tissues isolated from these
mice. Compared to wild-type control livers, the expression of
p18 and p27 in Men1-null livers was reduced 89% and 63%,
respectively (unpublished data). Collectively, these data
Figure 7. Hb9 Expression Is Elevated in Islets from Conventional and Conditional Men1 Knockout Mice
(A) Pancreatic sections from an 18-mo conventional Men1 knockout mouse (Men1
þ/ ) were analyzed for Hb9 expression by immunohistochemistry.
Brown stain corresponds to positive Hb9 signal. Compared to normal-size islets (left), an atypical hyperplastic islet (middle) and tumor (right) show
increased Hb9 expression. All pictures were taken from different regions of the same section, all at the same exposure. Top panels:3100 magnification,
bottom panels: 3200 to 3400.
(B) Real-time PCR analysis of Men1 and Hlxb9 expression in Men1
þ/þand Men1
 / islets from conditional animals. Blue bars indicate expression relative to
Gapdh; red bars, expression relative to beta-actin;þ/þ, average expression of five control mice (three RIP-Cre; Men1
þ/þ, two Men1
þ/þ); 15–25 wk Men1
 / ,
average of one pool of conditional islets at 15 wk (five) and three individual preps from 25-wk Men1
 /  islets (RIP-cre; Men1
loxP/loxP); and tumor, average
expression of five tumors from conditional Men1 knockout mice (RIP-cre; Men1
loxP/loxP). Asterisks denote statistical significance (p , 0.02) for both blue
and red bars as determined by two-tailed t-tests.
DOI: 10.1371/journal.pgen.0020051.g007
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p18 and p27 in both pancreatic islets and liver. Since the
absence of menin gives rise to tumors only in endocrine
pancreas, not in liver, mechanisms beyond simple dysregula-
tion of p18 and p27 must be involved.
Discussion
We set out to investigate menin’s role as a transcriptional
regulator by identifying genes bound by and dependent on
menin. Prior to this study, the only genes reported to be
targeted by menin and MLL were Hoxc6, Hoxc8, HOXA9, p27,
and p18. Our ﬁndings indicate that menin does not only
target speciﬁc classes of genes like HOX and CDK inhibitors
but that menin also targets a very broad range of promoters
in multiple tissues. This expands the realm of menin-targeted
genes several hundred-fold. We ﬁnd that menin occupancy
frequently coincides with members of the HMT complex,
MLL1 and Rbbp5, as well as the H3 K4 trimethyl mark, raising
the possibility that menin functions as a general transcrip-
tional regulator that helps maintain stable gene expression.
Averaged over thousands of genes, menin correlates with
higher gene expression, but overall expression levels do not
decrease upon loss of menin in null islets. Surprisingly, menin
binds many regions of the genome independently of the HMT
complex members, suggesting that menin may regulate
transcription by cooperating with other, currently unknown
proteins. Possible candidates include JunD, SMADs, NFjB, or
other menin-associated transcription factors not part of the
SET1/MLL complex.
A fundamental question for many tumor suppressor
syndromes is the tissue speciﬁcity of tumor formation. Menin
is expressed in nearly all tissues. Why do MEN1-associated
tumors arise primarily in endocrine organs? Could the
interactions between menin, MLL, and HOX gene expression
suggest an explanation for the endocrine speciﬁcity?
MLL is an important regulator of HOX gene expression,
and leukemic chromosomal translocations involving MLL
appear to act by creating chimeric fusion proteins that
constitutively activate HOX genes [33–35]. The persistent
expression of HOX genes results in a failure of terminal
differentiation, and studies in mice have shown that over-
expression of certain HOX genes, Hoxa9 and Meis1 in
particular, leads to leukemogenesis [36,37]. Previous studies
have also shown that menin can positively regulate HOXA9 in
HeLa cells and Hoxc6 and Hoxc8 in developing mouse embryo
[16,17]. Collectively, these ﬁndings have led to the enticing
hypothesis that tumorigenesis in MEN1, like leukemogenesis,
is related to dysregulation of HOX genes normally bound by
menin and MLL. If this hypothesis is valid, however, we would
have expected to see menin occupancy at the HOX clusters in
pancreatic islets. While we did detect extensive binding of
menin (and MLL) to the HOX A and C clusters in HeLa S3
cells, virtually no signal was detected in either HepG2 cells or
pancreatic islets. Moreover, the clustered homeobox genes
are expressed at almost undetectable levels in pancreatic
islets, and none of them signiﬁcantly change in expression
following loss of menin. Given these ﬁndings and the
contrasts of menin function in myeloid versus endocrine
tumors, we believe it is unlikely that dysregulation of HOX
genes in islet cells contributes to MEN1 islet neoplasms.
If HOX genes are not the mediator, then how does menin
loss lead to endocrine tumors? Menin was recently proposed
to regulate pancreatic islet growth by promoting histone
methylation and expression of cyclin-dependent kinase
inhibitors p27 and p18 [18,19]. Moreover, the simultaneous
loss of p18 and p27 in mice was shown to lead to development
of tumors in many of the same endocrine tissues as humans
with inherited mutations in the MEN1 and MEN2 genes [20].
These studies argue for a major role for p18 and p27 in the
tissue-speciﬁc tumor phenotype in MEN1. Speciﬁcally, loss of
menin prevents H3 K4 methylation at the promoters of p18
and p27, reducing their expression, and ultimately abrogating
their inhibitory effect on cyclin-dependent kinases (CDK2
and CDK4) and resulting in unrestrained cell growth.
Consistent with this hypothesis, we detected menin at the
promoters of p18 and p27 and reduced p18 expression in islet
cells that were conditionally null for Men1. However, p18 and
p27 concentrations were reduced in Men1
 /  liver, which is
not susceptible to developing tumors in heterozygous MEN1
patients, or in mice rendered null for menin in liver by a
conditional knockout. A separate study showed that menin
can regulate p18 and p27 expression in ﬁbroblasts [19], yet the
phenotype of MEN1 does not include ﬁbrosarcoma. These
results indicate that while dysregulation of p18 and p27 may
contribute to neoplastic transformation in MEN1, these genes
alone cannot account for the speciﬁc bias for endocrine
tumor formation in MEN1.
To identify other possible genetic causes for the tissue
speciﬁcity of tumor formation, we identiﬁed a relatively small
number of genes that were both bound by menin and altered
in expression in menin-null islets. One of these genes was the
developmentally programmed HLXB9, which codes for tran-
scription factor HB9. Hb9 expression was signiﬁcantly
elevated in pancreatic islets in the absence of menin,
suggesting that menin is a transcriptional repressor of
Figure 8. Hypothetical Model of Menin Function
See text.
DOI: 10.1371/journal.pgen.0020051.g008
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Genomic Occupancy of MeninHLXB9. It is also noteworthy that HLXB9 was bound by
menin only in islets, and not in HeLa or HepG2 cells. These
ﬁndings raise the possibility that the speciﬁc bias for
endocrine tumor formation in MEN1 could result from
changes in expression in distinct genes, including HLXB9,
that are speciﬁcally targeted by menin in endocrine tissues.
Based on our ﬁndings and the work of others, we propose
the following model for tumor suppression by menin in
pancreatic islets (Figure 8). In both endocrine and non-
endocrine tissues, menin mediates transcriptional activation
of genes that inhibit cell growth, including, but not limited to,
the cyclin-dependent kinase inhibitors p18 and p27.I n
addition, menin can function as a corepressor of tissue-
speciﬁc genes that promote cell growth, including HLXB9.
Menin can mediate its regulatory functions in the presence of
the HMT complexes or other menin partners. Endocrine
neoplasia as a consequence of menin loss results from the
combined effects of decreased p18 and p27 and increased
HLXB9 expression. Additional tissue-speciﬁc factors that are
dysregulated upon menin loss probably also contribute to
neoplasia. Similar studies in additional tissues, such as
anterior pituitary or parathyroid, may help reveal the
complete list of critical targets.
Materials and Methods
Antibodies for chromatin immunoprecipitation. Afﬁnity-puriﬁed
rabbit polyclonal anti-menin (BL342), anti-Rbbp5 (BL766), and anti-
MLL1 (BL1289) antibodies were obtained from Bethyl Laboratories
(Montgomery, Texas, United States). The menin antibody recognizes
an epitope at the C terminus of menin. The Rbbp5 antibody was
raised against a portion of human Rbbp5 encoded within exons 13
and 14. The epitope recognized by anti-MLL1 maps to a region
between residues 720 and 780 of MLL1. This epitope is found in the
N-terminal 300-kDa fragment generated by proteolytic cleavage.
Histone H3 K4 antibody (ab8580; Abcam, Cambridge, United
Kingdom) reacts to trimethylated H3 K4 and shows weak reactivity
to dimethylated H3 K4.
Microarrays used for ChIP-chip. Two different DNA tiling micro-
array designs were used in this study. Both microarrays were printed
by NimbleGen (Madison, Wisconsin, United States). The ﬁrst array
contained 190,181 oligonucleotides (70 nucleotides in length)
representing HOX clusters A, B, C, and D, and approximately 230
loci tiled at an average resolution of one oligo every 150 to 350 bp.
Roughly half of these 230 loci harbored genes whose protein products
contain homeodomains. The remaining half were identiﬁed as
positive ‘‘hits’’ in a pilot study using a previously described conven-
tional microarray that contained portions of promoter regions of
13,000 human genes (unpublished data). For each of these 230 genes,
oligonucleotides spanning 10 kb relative to the transcriptional start
site to þ10 kb relative to the end of the transcript were tiled. The
coordinates for DNA corresponding to the HOX clusters based on the
July 2003 human genome assembly are as follows: HOX A:
Chromosome 7: 16,875,358 to 36,981,974; HOX B: Chromosome 17:
47,064,003 to 47,300,285; HOX C: Chromosome 12: 52,599,536 to
52,755,746; HOX D: Chromosome 2: 177,140,087 to 177,277,119. The
second tiling microarray we designed contained oligonucleotides
tiled across 19,928 promoter regions. The oligonucleotides were
distributed at a resolution of approximately one 50 mer every 100 bp
(1.5 kb approximately each promoter region). This array also
contained tiling oligonucleotides across 381 genes ( 5 kb relative to
each transcriptional start site to þ5 kb relative to the end of each
transcript) at an average resolution of one oligo every 180 bp. The
array also harbored tiling oligonucleotides across all four HOX
clusters. The coordinates for DNA corresponding to the HOX clusters
were based on the May 2004 human genome assembly and are as
follows: HOX A: Chromosome 7: 26,901,743 to 27,173,542; HOX B:
Chromosome 17: 43,958,347 to 44,167,626; HOX C: Chromosome 12:
52,616,715 to 52,738,384; HOX D: Chromosome 2: 176,780,780 to
176,883,479.
ChIP-chip. The protocol described here was adapted from
previously published studies [21,38]. Brieﬂy, for each ChIP-chip
experiment, 1 to 2310
8 cells were crosslinked with 1% formaldehyde
for 20 min at room temperature, harvested, and rinsed with 13 PBS.
Cell nuclei were isolated, pelleted, and sonicated. DNA fragments
were enriched by immunoprecipitation with factor-speciﬁc anti-
bodies. After heat-reversal of the crosslinking, the enriched DNA was
ampliﬁed by ligation-mediated PCR (LM-PCR) and then ﬂuorescently
labeled by using Klenow polymerase and Cy5-labeled dUTP (Amer-
sham Biosciences, Piscataway, New Jersey, United States). A sample of
DNA that was not enriched by immunoprecipitation was subjected to
LM-PCR and labeled with Cy3-dUTP. ChIP-enriched and unenriched
(input) labeled samples were cohybridized to microarrays. Micro-
arrays were hybridized 18 to 20 h at 45 8C, washed according to the
protocol described by NimbleGen, and scanned using an Agilent
Technologies (Palo Alto, California, United States) microarray
scanner. As a pilot study, the ﬁrst custom-designed ‘‘HOX’’ array
was hybridized with menin chromatin immunoprecipitated DNA
from HeLa S3 cells from a single experiment. For experiments using
the second, more promoter-oriented array design, three biological
replicates were performed for experiments in HeLa S3 and HepG2
cells. In puriﬁed pancreatic islet preps, menin ChIP-chip was
performed in biological quadruplicate, and Rbbp5 and H3 K4
experiments in duplicate. Due to limited availability of primary islet
tissue, ChIP-chip in islet cells using antibodies to MLL1 was done
once. Islet preparations were treated with formaldehyde in culture
media between 1 h and 5 d after isolation from pancreata, which were
derived from brain-dead organ donors (National Institutes of Health,
Institutional Review Board exemption issued by National Institutes of
Health Ofﬁce of Human Subjects [IRB Exemption No. 3072]). For
each ChIP-chip experiment, approximately 30,000 viable islet
equivalents were ﬁxed and handled as described above. Islet purity
ranged from 40% to 90% with 60% to 90% viability.
Analysis of ChIP tiling array data. Raw array data were normalized
using bi-weight mean using the NimbleScan Version 2.1 software
(NimbleGen Systems). Log2 ratios (cy5/cy3) from biological replicates
were averaged. To identify potential sites of enrichment, a window
and threshold strategy was used (Figure 1). Brieﬂy, a 1,000-bp window
was moved stepwise along the tiled region, centering at every probe.
Hybridization signals of probes within each window were tested by v
2
analysis to determine if the window contained a higher than expected
number of probes. These calculations resulted in a single p-value
associated with each averaged data point. Analyses performed at
different window sizes and thresholds yielded similar results
(unpublished data). All raw and processed ChIP-chip data is publicly
available from Gene Expression Omnibus (GEO) (http://www.ncbi.
nlm.nih.gov/geo). The p-value scores for each promoter tested are
included. The windowing and threshold program we developed,
which we named ACME (Algorithm for Capturing Microarray
Enrichment), is available from the authors upon request.
Real-time PCR validation. Standard ChIP with menin and
trimethyl H3 K4 antibodies was performed on HeLa S3 cells in
duplicate. PCR primer pairs were designed to amplify 150- to 200-bp
fragments from selected genomic regions. For menin, we compared
67 promoters determined by ChIP-chip to be enriched for menin
binding at p , 0.0001 to 15 random promoter regions (0.001 , p , 1)
and seven random regions located outside of promoter regions. For
H3 K4, we tested 38 promoters that were determined by ChIP-chip to
be highly enriched (p , 0.0001), 20 marginally enriched genes (0.0001
, p , 0.001), 17 unenriched promoter regions (p . 0.5), and seven
random regions.
Real-time PCRs were carried out in duplicate on each chromatin
immunoprecipitated and input DNA sample using SYBR green PCR
mix (Qiagen, Valencia, California, United States) in an Applied
Biosystems 7900HT Fast Real Time-PCR machine (Foster City,
California, United States). DNA obtained from menin chromatin
immunoprecipitations was very limited in quantity and could not be
quantitated by standard methods. As a result, unequal quantities of
ChIP and input DNA were added to PCRs. To account for the
differences in DNA quantity, for every genomic region studied, a DCt
value was calculated for each sample by subtracting the Ct value for
chromatin immunoprecipitated sample from the Ct value obtained
for the input. Raising 2 to the DCt power yielded the relative amount
of PCR product (relative enrichment). Average values for promoters
occupied by either menin or H3 K4 were compared to those
calculated for unoccupied promoters and random regions of the
genome. All primer sequences are available upon request.
Comparison of ChIP-chip and expression data. ChIP-chip data
from islet cells were merged to Affymetrix (Santa Clara, California,
United States) islet expression data from the Novartis (version 2) data
set [39]. HeLa S3 and HepG2 ChIP-chip data were merged to
expression data generated in our laboratory using Affymetrix U133A
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datasets were merged by gene symbol. For all three cell types, two
replicate datasets were averaged. Average raw intensity values were
converted to log base 2 and normalized using the robust multiarray
average method (RMA) [40]. Data for genes represented by multiple
probes were retained in the dataset. This analysis gave 10,148 genes in
islet cells and 10,078 genes in HeLa S3 and HepG2 cells for which we
had both binding and expression data.
Microarray analyses were also performed using RNA from highly
pure islets prepared from 15-wk-old (n ¼ 5) and 25-wk-old (n ¼ 3)
female mice that were conditionally null for Men1 (genotype: RIP-cre,
Men1
loxP/loxP). Controls included islet RNA prepared from sex-
matched wild-type (n ¼ 3) and RIP-cre (n ¼ 2) mice at 15 wk of age.
Total RNA isolated from each group of mice was pooled and
subjected to two rounds of ampliﬁcation three times. Biotin-labeled
cRNA was then puriﬁed, fragmented, and hybridized to MOE430A
Affymetrix GeneChip probe arrays containing more than 22,000
probe sets. Two-tailed t-tests using Microsoft Excel were used to
compare expression values from wild-type and RIP-cre controls to
15-wk conditionally null mice (RIP-cre, Men1
loxP/loxP). The mouse
expression data were merged to the human ChIP-chip data, yielding
5,519 unique genes for which we had both expression and binding
data.
Immunohistochemistry. The pancreas from an 18-mo heterozy-
gous Men1 knockout mouse (Men1
þ/ ) was removed, immediately ﬁxed
in 4% paraformaldehyde, and embedded in parafﬁn. Immunohisto-
chemistry of pancreatic sections from an 18-mo conventional Men1
knockout mouse (Men1
þ/ ) was performed following antigen retrieval
using previously described antibodies to Hb9 [25].
Supporting Information
Figure S1. The 184 Genes That Were Found to Separate 15-wk Men1-
Null Islets from Controls Are Depicted in the Red-Green Color-
Coded Plot (p , 0.01)
Relative expression levels have been pseudo-colored red and green,
with red corresponding to high expression and green corresponding
to low expression. The color-coded plot to the right of the expression
data represents ChIP-chip p-value binding data for each factor. Color
key: red, p , 0.0001; orange, 0.0001 . p , 0.001; gold, 0.001 . p ,
0.01; light yellow, 0.01 . p ,0.1; white, p . 0.1. Twenty-four genes
whose promoters were bound by menin exclusively in islets are
depicted in red and blue. Those in red show statistically signiﬁcant
differences in expression at both the 15- and 25-wk time points (p ,
0.01).
Found at DOI: 10.1371/journal.pgen.0020051.sg001 (142 KB PDF).
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